SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced the launch of its collaboration with Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in the cell therapy space.

旧金山--（商业新闻短讯）--Multiply Labs是一家开发行业领先的自动化制造系统以生产个性化药物的机器人公司，今天宣布与细胞治疗领域的全球领导者Legend Biotech Corporation（NASDAQ:LEGN）（Legend Biotech）启动合作。

This initiative will be focused on automating cell therapy manufacturing, leveraging Multiply Labs’ unique approach which consists of robotic systems that can operate a wide variety of instruments already deployed in the cell and gene therapy industry. This collaboration holds the potential to enable a more rapid and seamless adoption of robotic technology, as opposed to traditional automation approaches that require substantial changes to the manufacturing process..

这项计划将集中于自动化细胞治疗制造，利用Multiple Labs独特的方法，该方法由机器人系统组成，可以操作已经部署在细胞和基因治疗行业的各种仪器。与传统的自动化方法相比，这种合作有可能使机器人技术的采用更加快速和无缝，而传统的自动化方法需要对制造过程进行实质性的改变。。

Through this collaboration, Legend Biotech will evaluate Multiply Labs’ robotic technologies, and secure priority access to these automated systems. The template for Multiply Labs’ approach - which will be evaluated through this collaboration - is the peer-reviewed study published earlier this year in Cytotherapy, which showed statistical equivalence between manual and automated cell expansion processes..

通过这次合作，联想生物技术公司将评估多实验室的机器人技术，并确保优先访问这些自动化系统。Multiply Labs方法的模板（将通过此次合作进行评估）是今年早些时候发表在《细胞疗法》上的同行评审研究，该研究显示手动和自动细胞扩增过程在统计学上是等效的。。

“This collaboration enables us to apply our technology in collaboration with some of the best scientists in our field, showcasing the power and potential of our flexible approach to automation and bringing us one step closer to our vision of reducing labor costs and, in the future, boosting manufacturing throughput,” said Fred Parietti, Ph.D., Co-founder and CEO of Multiply Labs.

Multiply Labs联合创始人兼首席执行官弗雷德·帕里蒂（FredParietti）博士说：“这种合作使我们能够与我们领域中一些最优秀的科学家合作应用我们的技术，展示了我们灵活的自动化方法的力量和潜力，并使我们离降低劳动力成本以及未来提高制造吞吐量的愿景更近了一步。”。

“We look forward to delivering more accessible treatment options to patients.”.

“我们期待着为患者提供更容易获得的治疗选择。”。

ABOUT MULTIPLY LABS

关于MULTIPLY LABS

Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space.

Multiply Labs是一家机器人公司，为制药行业提供自主制造技术。该公司开发了先进的云控制机器人系统，可以大规模生产个性化药物。其客户包括先进制药制造领域的一些最大的全球组织。

Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California.

Multiply Labs的专业知识是机器人技术和生物制药的交叉点，其团队包括机械工程师、电气工程师、计算机科学家、软件工程师和制药科学家。创始团队之所以取得联系，是因为他们在麻省理工学院共同热爱机器人。该公司总部位于加利福尼亚州旧金山。

For more information, please visit www.multiplylabs.com and follow us on LinkedIn..

有关更多信息，请访问www.multiplylabs.com并在LinkedIn上关注我们。。